Valneva : KOL Presentation on the Chikungunya Virus

KOL Presentation on the Threat of

Chikungunya Virus

Investor Webcast

May 25, 2022

Today's Agenda

Welcome and Introduction

Chikungunya In Depth

VLA1553 Update

Q&A

Joshua Drumm, Ph.D.

VP Global Investor Relations, Valneva

Bradley A. Connor, M.D.

World-renowned expert in tropical medicine and gastroenterology

Juan Carlos Jaramillo, M.D.

Chief Medical Officer, Valneva

Joined by:

Peter Bühler; Chief Financial Officer, Valneva

Katrin Dubischar; VP, Chikungunya Program Director, Valneva

2

Speaker Introductions

Bradley A. Connor, M.D.

• Clinical Professor of Medicine at the Weill Cornell Medical College
• Attending Physician at the New York Presbyterian Hospital - Cornell Campus
• Founder and Medical Director of the New York Center for Travel and Tropical Medicine
• NYC Site Director for the CDC's Emerging Infectious Disease network
• Past president of the International Society of Travel Medicine (ISTM)

Juan Carlos Jaramillo, M.D.

• Experienced R&D leader with broad expertise
• Daiichi Sankyo - SVP, market access and medical affairs; SVP, head of global market access and pricing
• Grünenthal - SVP, medical affairs and clinical development
• Previous roles at GlaxoSmithKline

3

Disclaimer

This presentation does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, Valneva SE shares to any person in the USA or in any jurisdiction to whom or in which such offer or solicitation is unlawful.

Valneva is a European company. Information distributed is subject to European disclosure requirements that are different from those of the United States. Financial statements and information may be prepared according to accounting standards which may not be comparable to those used generally by companies in the United States.

This presentation includes only summary information provided as of the date of this presentation only and does not purport to be comprehensive. Any information in this presentation is purely indicative and subject to modification at any time without notice. Valneva does not warrant the completeness, accuracy or correctness of the information or opinions contained in this presentation. None of Valneva, or any of its affiliates, directors, officers, advisors and employees is under any obligation to update such information or shall bear any liability for any loss arising from any use of this presentation. The information has not been subject to independent verification and is qualified in its entirety by the business, financial and other information that Valneva is required to publish in accordance with the rules, regulations and practices applicable to companies listed on Euronext Paris and the NASDAQ Global Select Market, including in particular the risk factors described in Valneva's universal registration document filed with the French Financial Markets Authority (Autorité des Marchés Financiers, or AMF) on March 23, 2022 and the Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on March 24, 2022, as well as the information in any other periodic report and in any other press release, which are available free of charge on the websites of Valneva (www.valneva.com) and/or the AMF (www.amf-france.org) and SEC (www.sec.gov).

Certain information and statements included in this presentation are not historical facts but are forward-looking statements, including statements with respect to revenue guidance, the progress, timing, completion results of research, development and clinical trials for product candidates and estimates for future performance. The forward-looking statements (a) are based on current beliefs, expectations and assumptions, including, without limitation, assumptions regarding present and future business strategies and the environment in which Valneva operates, and involve known and unknown risk, uncertainties and other factors, which may cause actual results, performance or achievements to be materially different from those expressed or implied by these forward-looking statements, (b) speak only as of the date this presentation is released, and (c) are for illustrative purposes only. Investors are cautioned that forward-looking information and statements are not guarantees of future performances and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Valneva.

This presentation presents information about VLA1553, an investigational vaccine candidate that has not been approved for use and has not been determined by any regulatory authority to be safe or effective.

4

The Threat of Chikungunya Disease

Bradley Connor, M.D.